I. COMMENCED TRADING IN AUGUST

INITIAL OFFERINGS

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out (M)

Lead, Other
Underwriters

Gross
(M)

Net
(M)


There were no initial public offerings in August.

Total: $0M

Number of IPOs in August: 0

Average value of August IPOs: $0M

Number of IPOs for 2001: 7

Total raised in IPOs in 2001: $207.05M

Average value of IPOs in 2001: $29.58M

FOLLOW-ON OFFERINGS

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out (M)

Lead, Other
Underwriters

Gross
(M)

Net
(M)


Atrix Laboratories
Inc.
(ATRX)1

2/15

8/9

3.45S

$23

18.2

Bank of America Securities; U.S. Bancorp Piper Jaffray (co-leads); CIBC World Markets Corp.; Gruntal & Co. LLC

$79.4

$74.2

ConjuChem Inc.
(Canada; TSE:
CJC)2

5/30

8/24

3.83S

C$6.25
(US$4.07)

26

Yorkton Securities Inc.; BMO Nesbitt Burns Inc.; HSBC Securities Inc.

C$23.95
(US$15.6)

C$17.1
(US$11)

Vion
Pharmaceuticals
Inc.
(VION)3

4/3

8/10

2.5S

$5

26.3

Gerard Klauer Mattison & Co.; C.E. Unterberg, Towbin (co-leads)

$12.5

$11.4

EXERCISED OVERALLOTMENT OPTIONS

Inflazyme
Pharmaceuticals
Ltd.
(Canada;
TSE:IZP)4

6/19

8/9

0.375S

C$2.70
(US$1.76)

N/A

RBC Dominion Securities Inc.; CIBC World Markets Corp.; Yorkton Securities Inc.; Dlouhy Merchant Group

C$1
(US$0.66)

N/A

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

AMEX = American Stock Exchange; TSE = Toronto Stock Exchange

1. Atrix's offering includes the exercise of the underwriters' overallotment option for 450,000 shares.

2. ConjuChem's offering includes the sale of 3M shares completed in June and the sale of 831,400 shares covering the underwriters' overallotment option exercised in August. The offering also included an additional 3.1M shares from shareholders. The net proceeds amount does not include the overallotment option.

3. Vion's underwriters have an overallotment option for 375,000 shares.

4. Inflazyme completed its $10.1M offering in July. In August, it raised an additional US$659,071 through the exercise of the overallotment option for 375,000 shares.

Total: $107.5M

Number of follow-on offerings in August: 3

Average value of August follow-ons: $35.8M

Number of follow-on offerings in 2001: 25

Total raised in follow-ons in 2001: $1,962.47M

Average value of follow-ons in 2001: $78.5M

II. FILED AND PENDING

INITIAL OFFERINGS

Company (Symbol/Proposed Symbol)#*

Date
Filed

Shares/
Units (M)

Price
Range

Shares
Out (M)

Lead, Other
Underwriters

Value
(M)


AgraQuest Inc.
(AGRQ)1

8/6

N/A

N/A

N/A

Merrill Lynch & Co.; Stephens Inc.;
First Union Securities Inc.

$75

APBiotech
(APBI; unit of
Nycomed
Amersham plc)2

10/3

18.2S

$15-17

208.6

Morgan Stanley Dean Witter (co-lead); Goldman, Sachs & Co. (co-lead); Chase H&Q; Salomon Smith Barney

$291.2

BioNumerik
(BNPI)3

3/2

N/A

N/A

N/A

Morgan Stanley Dean Witter; UBS Warburg LLC; SG Cowen Securities Corp.

$50

CombiMatrix
Corp.
(CLMX)4

11/22

N/A

N/A

N/A

Salomon Smith Barney (co-lead); J.P. Morgan & Co. (co-lead)

$100

diaDexus Inc.
(DDXS)5

11/20

7S

$12-14

31.1

Lehman Brothers Inc.; CIBC World Markets Corp.; Robertson Stephens Inc.; Fidelity Capital Markets

$91

NetGenics Inc.
(NTGC)6

3/13/00

5.5S

$11-13

23.5

Chase H&Q; UBS Warburg LLC

$66

Northwest
Biotherapeutics
Inc.
(NWBT)7

8/13

N/A

N/A

N/A

C.E. Unterberg, Towbin

$48.3

Ribapharm Inc.
(RIBA)8

5/15

18S

$13-15

N/A

UBS Warburg LLC; CIBC World Markets Corp.

$252

Senomyx Inc.
(SNMX)9

2/21

N/A

N/A

17.4

Deutsche Banc Alex. Brown; Bear, Stearns & Co. Inc.; CIBC World Markets Corp.

$80

Xcyte Therapies
Inc.
(XCYT)10

12/22

N/A

N/A

N/A

SG Cowen Securities Corp. (co-lead); U.S. Bancorp Piper Jaffray (co-lead); Dain Rauscher Inc.; First Security Van Kasper Inc.

$86.2

FOLLOW-ON OFFERINGS

Aastrom
Biosciences Inc.
(ASTM)11

12/7

7.7S

$0.96

33.84

N/A

$7.392

Alexion
Pharmaceuticals
Inc.
(ALXN)12

10/6

N/A

N/A

N/A

N/A

$300

Ariad
Pharmaceuticals
Inc.
(ARIA)13

6/22

4.5S

$4.79

34.6

N/A

$21.6

Cell Pathways
Inc.
(CLPA)14

2/7

N/A

N/A

N/A

N/A

$25

Cerus Corp.
(CERS)15

8/13

N/A

N/A

15.7

N/A

$300

Chiron Corp.
(CHIR)16

6/7

5.2S

$6.19

190

N/A

$400

Exelixis Inc.
(EXEL)17

7/30

N/A

N/A

48

N/A

$150

ICOS Corp.
(ICOS)18

6/26

N/A

N/A

53

N/A

$300

InSite Vision
Inc.
(AMEX:
ISV)19

2/2

N/A

N/A

N/A

Ladenburg Thalmann & Co. (placement agent)

$40

Matrix
Pharmaceuticals
Inc.
(MATX)20

5/25

N/A

N/A

26

N/A

$30

Medarex Inc.
(MEDX)21

6/19

N/A

N/A

72.7

Goldman Sachs & Co.; Credit Suisse First Boston; JP Morgan; Morgan Stanley Dean Witter; Bear, Stearns & Co. Inc.; Dain Rauscher Wessels

$175

Microcide
Pharmaceuticals
Inc.
(MCDE)22

2/12

N/A

N/A

N/A

N/A

$35

NeoTherapeutics
Inc.
(NEOT)23

1/3

N/A

N/A

20.8

N/A

$50

Telik Inc.
(TELK)24

8/20

4S

$10

26.9

Lehman Brothers Inc.; Legg Mason Wood Walker; UBS Warburg LLC; Lazard Freres & Co. LLC; Needham and Company Inc.

$40

Tularik Inc.
(TLRK)25

8/14

N/A

N/A

N/A

N/A

$250

ViroPharma Inc.
(VPHM)26

7/3

N/A

N/A

18.7

N/A

$300

Vysis Inc.
(VYSI)27

8/8

1S

$25.96

11.2

UBS Warburg LLC; First Union Securities Inc.; Pacific Growth Equities Inc.

$26

III. WITHDRAWN AND POSTPONED

INITIAL OFFERINGS

Company (Symbol/Proposed Symbol)#*

Date
Filed/
Date Pulled

Shares/
Units (M)

Price
Range

Shares
Out (M)

Lead, Other
Underwriters

Value
(M)


Acadia
Pharmaceuticals
Inc.
(ACAD)28

12/21
8/31

5S

$13-15

15.8

Robertson Stephens Inc. (co-lead); U.S. Bancorp Piper Jaffray (co-lead)

$75

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

N/A = Not available or reported.

AMEX = American Stock Exchange; TSE = Toronto Stock Exchange

1. AgraQuest filed a registration statement with the SEC to raise $75M in an IPO.

2. APBiotech's IPO value, $291.2M, is based on the sale of 18.2M shares at $16 each, the midpoint of the expected price range.

3. BioNumerik filed for a $50M IPO. The number of shares to be offered, the price range, and the number of shares outstanding were not disclosed.

4. CombiMatrix did not disclose any further details.

5. diaDexus' IPO value, $91M, is based on the sale of 7M shares at $13, the midpoint of the expected price range. The underwriters have an overallotment option for 1.05M shares.

6. NetGenics' IPO value, $66M, is based on the sale of 5.5M shares at $12 each, the midpoint of the expected price range. The underwriters have an overallotment option for 825,000 shares.

7. Northwest filed for an IPO expected to raise $48.3M.

8. Ribapharm's IPO originally was proposed in June 2000. The company amended its prospectus on May 15. The value, $252M, is based on the offering of 18M shares at $14 each, the midpoint of the expected price range. The underwriters have an overallotment option for 2.7M shares.

9. Senomyx did not disclose any further details.

10. Xcyte did not disclose any further details.

11. Aastrom amended its prospectus 12/29 increasing the offering from 6.35M shares to 7.7M shares. The offering value, $7.4M, is based on the proposed maximum aggregate price of $0.96 per share. The company placed 1.18M shares in a private placement in May, raising $1.1M. The company placed 1.89M shares in private placements in June, raising $2.95M. It also placed 1.05M shares in July, raising $1.5M. And it placed 3.3M shares in August, raising $5M.

12. Alexion filed a shelf registration to offer common stock, debt or warrants, up to a value of $300M.

13. Ariad's offering value is based on the proposed maximum offering share price of $4.79.

14. Cell Pathways filed a shelf registration for the sale of $25M in common stock.

15. Cerus filed to sell up to $300M of common stock and debt in a shelf offering.

16. Chiron Corp. plans to raise $400M through an offering of 30-year liquid yield option notes that could equate to 5.2M shares.

17. Exelixis filed a shelf registration to sell up to $150M in common stock.

18. ICOS filed a shelf registration statement for up to $300M.

19. InSite filed a shelf registration to sell $40M in stock

20. Matrix filed a shelf registration covering up to $30M in securities.

21. Medarex plans to raise $175M through an offering of convertible notes due 2006. The offering will include an overallotment option for $26.25M principal amount of the notes to cover overallotments.

22. Microcide filed a shelf registration for the sale of up to $35M in securities.

23. NeoTherapeutics filed a shelf registration covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. The company amended its prospectus April 19. In August, the company privately placed 600,000 shares, raising $2.01M.

24. Telik's underwriters have an option to purchase 600,000 additional shares. The proceeds are based on an estimated offering price of $10 per share.

25. Tularik filed to sell up to $250M in common stock and debt securities.

26. ViroPharma filed a universal shelf registration for $300M in mixed securities.

27. Vysis registered to sell 4M shares, 3M of which will be sold by shareholder BP plc. The value of the offering, $26M, is based on the closing stock price of $25.96 on Aug. 7. The underwriters have an overallotment option for 600,000 shares.

28. Acadia withdrew its IPO due to market conditions.

No Comments